Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial

医学 安慰剂 临床终点 物理疗法 随机对照试验 髋部骨折 人口 外科 体质指数 临床试验 内固定 内科学 骨质疏松症 替代医学 病理 环境卫生
作者
Lorenz Christian Hofbauer,Richard Witvrouw,Zsuzsanna Varga,Naofumi Shiota,Malika Cremer,László B. Tankó,Daniel Rooks,Lixin Zhang Auberson,Michał Arkuszewski,Nathalie Fretault,Agnes Annette Schubert-Tennigkeit,Dimitris A. Papanicolaou,Chris P. Recknor
出处
期刊:The Lancet Healthy Longevity [Elsevier BV]
卷期号:2 (5): e263-e274 被引量:44
标识
DOI:10.1016/s2666-7568(21)00084-2
摘要

BACKGROUND: Older adult patients (ie, those aged ≥60 years) undergoing surgery for hip fracture repair frequently experience loss of muscle mass and strength due to poor mobility and delayed functional recovery. No proven treatment is currently available to enhance recovery of physical function in this growing patient population. This study aimed to investigate whether bimagrumab, a human monoclonal antibody targeting activin type 2 receptors, can improve post-surgical recovery. METHODS: who had undergone internal fixation or hemiarthroplasty for a proximal femoral fracture (confirmed by radiography) in the previous 6 weeks were eligible. Patients with a history of a high-energy subtrochanteric fracture or any other lower limb fracture in the past 6 months, or any major surgery of the lower limbs in the past 3 months were excluded. Participants were randomly assigned (2:1:2:2) via interactive response technology to receive intravenous treatment with placebo, bimagrumab 70 mg, bimagrumab 210 mg, or bimagrumab 700 mg every 4 weeks for 24 weeks. Participants, investigators, site personnel, and study sponsor personnel in participating countries were masked to treatment assignment. The primary endpoint was the change from baseline in total lean body mass, measured by dual-energy x-ray absorptiometry, at week 24 in the full analysis set, which included all randomised participants who had received at least one dose of the assigned treatment. Key secondary endpoints included changes in habitual gait speed (measured in m/s) and short physical performance battery score between baseline and 24 weeks. Safety and tolerability were assessed by recording adverse events and vital signs on weeks 4, 8, 12, 24, and 48, and by laboratory assessments and electrocardiography at the screening visit and on days 1, 84, and 168. Safety was assessed in all randomised participants who had received at least one dose of study drug, analysed according to treatment received. This study was registered with ClinicalTrials.gov, NCT02152761. FINDINGS: Between Sept 16, 2014, and Dec 15, 2017, 384 patients were screened, of whom 250 patients were enrolled and randomly assigned to the placebo group (n=72), the bimagrumab 70 mg group (n=34), the bimagrumab 210 mg group (n=69), or the bimagrumab 700 mg group (n=75). A total of 207 (83%) participants completed the 24-week treatment period. There was a significant absolute increase in lean body mass from baseline compared with placebo (0·2 kg [SD 2·0]) in the bimagrumab 210 mg group (1·9 kg [1·7]; p<0·0001) and in the bimagrumab 700 mg group 2·8 kg [2·2]; p<0·0001) but not in the bimagrumab 70 mg group (0·6 kg [SD 2·2]; significance not assessed). Changes in habitual gait speed and short physical performance battery scores between baseline and week 24 were not significantly different across the treatment groups, suggesting no enhancement of physical recovery with bimagrumab over placebo. Bimagrumab was safe and well tolerated. The most frequently reported treatment-emergent adverse events were falls (six [18%] of 34 participants in the bimagrumab 70 mg group; 12 [17%] of 69 participants in the bimagrumab 210 mg group; 14 [19%] of 75 participants in the bimagrumab 700 mg group; and 13 [18%] of 72 participants in the placebo group), muscle spasms (two [6%] in the bimagrumab 70 mg group; 17 [25%] in the bimagrumab 210 mg group; 12 [16%] in the bimagrumab 700 mg group; and six [8%] in the placebo group), and arthralgia (five [15%] in the bimagrumab 70 mg group; six [9%] in the bimagrumab 210 mg group; nine [12%] in the bimagrumab 700 mg group; and five [7%] in the placebo group). Six deaths were reported during the study, none of which were considered by investigators as related to the study drug. INTERPRETATION: Bimagrumab treatment for 24 weeks led to dose-dependent, significant increases in lean body mass in older patients recovering from hip fracture surgery when compared with placebo. However, no functional benefit was observed in recovery of mobility or lower extremity function following bimagrumab treatment compared with placebo. FUNDING: Novartis Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Cold发布了新的文献求助10
1秒前
1秒前
1秒前
尘南浔发布了新的文献求助10
2秒前
2秒前
2秒前
yishu发布了新的文献求助10
2秒前
llllllll发布了新的文献求助10
2秒前
易夏完成签到,获得积分20
3秒前
3秒前
3秒前
摇滚谬中庸完成签到 ,获得积分10
3秒前
负责的书易完成签到,获得积分10
3秒前
丘比特的应助被科研通管家采纳,获得10
4秒前
4秒前
4秒前
NexusExplorer的应助被科研通管家采纳,获得10
4秒前
英俊的铭的应助被科研通管家采纳,获得10
4秒前
李雅欣发布了新的文献求助10
4秒前
CB发布了新的文献求助10
4秒前
科研通AI65的应助被科研通管家采纳,获得10
4秒前
NexusExplorer的应助被科研通管家采纳,获得10
4秒前
banana的应助被科研通管家采纳,获得10
4秒前
华仔的应助被科研通管家采纳,获得10
5秒前
英俊的铭的应助被mm采纳,获得10
5秒前
小二郎的应助被科研通管家采纳,获得10
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
Maestro_S的应助被科研通管家采纳,获得10
5秒前
李峥发布了新的文献求助10
5秒前
5秒前
李TB发布了新的文献求助10
6秒前
Akim的应助被科研通管家采纳,获得10
6秒前
大个的应助被科研通管家采纳,获得10
6秒前
bkagyin的应助被科研通管家采纳,获得10
6秒前
6秒前
灵巧绿海发布了新的文献求助10
6秒前
漆漆发布了新的文献求助10
6秒前
科目三的应助被科研通管家采纳,获得10
6秒前
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193438
求助须知:如何正确求助?哪些是违规求助? 9579666
关于积分的说明 21866723
捐赠科研通 7793099
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560719
邀请新用户注册赠送积分活动 2484156